MedTrace Logo

ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

NCT03897543 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-03-26

No results posted yet for this study

Summary

Open-label, uncontrolled, phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

ABX196

ABX196 will be administered as an IM injection 120 minutes (+/- 15 minutes) after the completion of the nivolumab infusion on Day 1 of every other 28-Day treatment cycle (i.e., every 8 weeks).

Sponsors & Collaborators

  • C3 Research Associates

    collaborator UNKNOWN

  • Abivax S.A.

    lead INDUSTRY

Principal Investigators

  • Darren SIGAL, MD · Scripps Clinic/Scripps MD Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-30
Primary Completion
2021-06-30
Completion
2023-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03897543 on ClinicalTrials.gov